Abstract: There are two types of HPV vaccines, domestic and imported. The main differences between domestic HPV vaccines and imported HPV vaccines are differences in type, vaccine carrier, safety, and price. Relatively speaking, domestic HPV vaccines The advantages of the vaccine are favorable price, high protection rate, small adverse reactions, and high production capacity. The main disadvantage is that only the bivalent HPV vaccine is available for the time being. The quadrivalent and nine-valent vaccines are still in the clinical trial stage and will need to wait for a while before they can be launched on the market. Let’s take a look at the differences between domestically produced HPV vaccines and imported ones. 1. What is the difference between domestic HPV vaccine and imported HPV vaccine?
The HPV vaccine is a vaccine to prevent cervical cancer and other diseases. According to the place of production, it can be divided into two types: domestic HPV vaccine and imported HPV vaccine. So the two types of HPV What's the difference between vaccines?
The domestic HPV vaccine is produced in my country. Compared with the imported HPV vaccine, the main differences are:
1. Different types. The domestic HPV vaccine currently only has a bivalent vaccine, which requires four doses. HPV vaccines with 9 or 9 prices are only imported.
2. Vaccine carriers are different. The domestic HPV vaccine uses E. coli as the carrier and is safe; the imported HPV vaccine bivalent vaccine contains latex ingredients, and the quadrivalent and nine-valent vaccines contain yeast ingredients.
3. In addition, the number of injections of the domestic HPV vaccine is also different. For girls aged 9-14, only two injections are needed, while the imported HPV vaccine requires three injections regardless of the price. of.
4. In terms of price, domestic HPV vaccines are cheaper than imported HPV vaccines.
2. What are the advantages of domestic HPV vaccines compared with imported vaccines
1. Price concessions
The prices of imported HPV vaccines are generally high, such as nine-price The full cost of the vaccine is about 3,900 yuan, and the bivalent vaccine is nearly 1,800 yuan. Based on the domestic HPV vaccine price of 329 yuan/tube, the full vaccination from 9 to 14 years old costs 658 yuan, and the vaccination for older age is 987 yuan. It is an imported bivalent vaccine. Half the price.
2. High protection rate and small adverse reactions
According to the clinical trial analysis report, the domestic vaccine has a high protection rate in preventing precancerous lesions related to HPV16 and 18 types. It is equal to or equal to other quadrivalent and bivalent HPV vaccines; in terms of effectiveness in preventing persistent infection of HPV types 16 and 18, the protection rate is higher than or equal to foreign bivalent and quadrivalent vaccines, and the adverse reactions are mild.
3. High production capacity
Domestic vaccines are different from the insect cell production system or recombinant Saccharomyces cerevisiae production system of foreign HPV vaccines, using DNA recombinant technology to express virus-like particle antigens in E. coli and used it for vaccine production. Its production system has high production capacity and low cost. The first batch of domestically produced HPV vaccines on the market totaled more than 90,000 doses.
3. Does the domestic HPV vaccine have nine prices?
As we all know, the higher the "price" of the HPV vaccine, the better the prevention effect. Therefore, many female friends want to take the nine-price HPV vaccine. So Is there a nine-price domestic HPV vaccine?
For now, domestically produced HPV vaccines are only bivalent, and quadrivalent and nine-valent HPV vaccines are still in clinical preparation. A query on the National Drug Clinical Trial Registration and Information Disclosure Platform found that recombinant human papilloma The research and development of the viral nine-valent vaccine (Escherichia coli) has now entered the Phase II clinical trial stage, and it will take some time before the domestic nine-valent HPV vaccine is successfully launched.